Next Article in Journal
Theophylline
Next Article in Special Issue
The Impact of Residual Symptoms in Major Depression
Previous Article in Journal
2-Deoxystreptamine Conjugates by Truncation–Derivatization of Neomycin
Previous Article in Special Issue
Nitric Oxide Synthase Inhibitors as Antidepressants
Open AccessReview

Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment

Department of Behavioural and Molecular Neuroendocrinology, University of Regensburg, Universitätsstr 31, Regensburg D-93053, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(3), 702-724; https://doi.org/10.3390/ph3030702
Received: 24 January 2010 / Revised: 24 February 2010 / Accepted: 5 March 2010 / Published: 16 March 2010
(This article belongs to the Special Issue Antidepressants)
Affective disorders represent the most common psychiatric diseases, with substantial co-morbidity existing between major depressive disorders (MDD) and anxiety disorders. The lack of truly novel acting compounds has led to non-monoaminergic based research and hypotheses in recent years. The large number of brain neuropeptides, characterized by discrete synthesis sites and multiple receptors, represent likely research candidates for novel therapeutic targets. The present review summarises the available preclinical and human evidence regarding the neuropeptide, oxytocin, and its implications in the aetiology and treatment of MDD. While the evidence is not conclusive at present additional studies are warranted to determine whether OXT may be of therapeutic benefit in subsets of MDD patients such as those with comorbid anxiety symptoms and low levels of social attachment. View Full-Text
Keywords: neuropeptide; depression; oxytocin; social attachment; early-life neuropeptide; depression; oxytocin; social attachment; early-life
MDPI and ACS Style

Slattery, D.A.; Neumann, I.D. Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment. Pharmaceuticals 2010, 3, 702-724.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop